Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Α. Dimopoulos, Pieter Sonneveld, Massimo Offidani et al.|Journal of Clinical Oncology|2018Cited by 71
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With LenalidomideBarbara Gamberi, Igor Wolfgang Blau, Christian Berthou et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2
European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and BortezomibBarbara Gamberi, Igor Wolfgang Blau, Miguel‐Teodoro Hernández et al.|Blood|2016Cited by 1